A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
← catalyst calendarNCT07284797 · readout ≤ 804 d
Sponsored by Xencor, Inc. (industry) · XNCR — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
60estimated
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-24 | actual | When the study began enrolling |
| Primary completion | Oct 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy
- Idiopathic Inflammatory Myopathies
- Systemic Sclerosis
- Sjögren's Disease
Intervention
- Biological: XmAb657
Primary outcome
what the primary-completion date above is the date OFPercentage of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
measured Through Week 52
Permalink · XNCR's whole pipeline · Catalyst calendar · Every registered study · What changed